Advances in radiation oncology · 2026
Temporally-Modulated Pulsed Radiation Therapy for Large-Volume Reirradiation of Recurrent Meningioma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eckelmann Bradley, Frenkel Amy, Burr Adam, Witt Jacob, Ahmed Azam, Bhatia Ankush, Tomé Wolfgang A, Bayliss Adam, Morris Brett
Аннотация
PURPOSE: Patients with recurrent meningiomas treated with prior radiation therapy have limited treatment options. This study aims to evaluate the efficacy and tolerability of reirradiation with temporally-modulated pulsed radiation therapy (TMPRT) in a cohort of patients with recurrent meningioma.
METHODS AND MATERIALS: We retrospectively identified 26 patients with recurrent meningioma treated with TMPRT from 2003 to 2025 at a single institution. All patients had radiographic or pathologic evidence of progression, were not candidates for radiosurgery or surgery, had previously received conventionally fractioned radiation therapy, and were retreated with temporally-modulated pulsed radiation therapy. Radiographic progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Acute and late toxicities were graded based on Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Overall survival and progression-free survival (PFS) were estimated using the Kaplan-Meier method.
RESULTS: Median follow-up was 61.9 months. Median TMPRT dose was 54 Gy in 2 Gy fractions. Median planning treatment volume was 193 cm3. PFS at 6 months was 77% (95% CI, 56%-89%) and median PFS was 27.2 months (95% CI, 7.5-46.5 months). Median overall survival was 27.2 months (95% CI, 16.4-73.9 months). Three patients (12%) experienced grade ≥3 acute toxicity, 3 patients (12%) experienced grade ≥3 late toxicity.
CONCLUSIONS: TMPRT was effective and generally well-tolerated in a cohort of patients with recurrent meningioma previously treated with radiation therapy. This represents the largest-volume reported reirradiation meningioma cohort, and suggests that TMPRT may safely expand the role of photon reirradiation to a patient population with limited local treatment options.
METHODS AND MATERIALS: We retrospectively identified 26 patients with recurrent meningioma treated with TMPRT from 2003 to 2025 at a single institution. All patients had radiographic or pathologic evidence of progression, were not candidates for radiosurgery or surgery, had previously received conventionally fractioned radiation therapy, and were retreated with temporally-modulated pulsed radiation therapy. Radiographic progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Acute and late toxicities were graded based on Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Overall survival and progression-free survival (PFS) were estimated using the Kaplan-Meier method.
RESULTS: Median follow-up was 61.9 months. Median TMPRT dose was 54 Gy in 2 Gy fractions. Median planning treatment volume was 193 cm3. PFS at 6 months was 77% (95% CI, 56%-89%) and median PFS was 27.2 months (95% CI, 7.5-46.5 months). Median overall survival was 27.2 months (95% CI, 16.4-73.9 months). Three patients (12%) experienced grade ≥3 acute toxicity, 3 patients (12%) experienced grade ≥3 late toxicity.
CONCLUSIONS: TMPRT was effective and generally well-tolerated in a cohort of patients with recurrent meningioma previously treated with radiation therapy. This represents the largest-volume reported reirradiation meningioma cohort, and suggests that TMPRT may safely expand the role of photon reirradiation to a patient population with limited local treatment options.